First-In-Human Clinical Study for Treatment of Severe Mitral Valve INsufficiency With Epygon™ TRanscatheter Mitral VAlve System
A legfontosabb adatok
- Ki végzi
- Epygon
- Hol
- Ausztria, Olaszország, Spanyolország és Szerbia10 helyszín, 4 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 40 fő, tervezett
- Kezdés
- 2021. febr. 1.
- Várható befejezés
- 2029. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Epygon™ Transcatheter Mitral Valve System
- A regiszteradat frissítve
- 2023. augusztus 7.
Ki vehet részt
- Életkor
- 60 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 35 feltétel megnézéseKevesebb
Ki vehet részt
- Patients of age ≥ 60 years
- Patients with primary or secondary severe symptomatic mitral valve regurgitation
- Patients with severe, symptomatic mitral regurgitation and who have been evaluated by a multidisciplinary Heart Team and deemed to be ineligible for conventional valve surgery and not eligible for transcatheter repair
- Patients with a left ventricular ejection fraction ≥ 30%
- Patients in NYHA functional classes III to IV
- Patients who have clearly accepted participation in this clinical study and who have signed the informed consent
- Patients who are willing to accept and undergo all protocol related requirements
- Patients not planning to transfer abroad
Ki nem vehet részt
- Patients involved in other clinical assessments for drugs or devices that could interfere or alter the study endpoints
- Patients who have previously undergone implantation of a transcatheter aortic valve prosthesis
- Patients with previous implantation of a mitral heart valve prosthesis
- Patients with previous implantation of a mitral annuloplasty ring
- Patients with an active peptic ulcer or upper GI bleeding within the prior 30 days
- Patients with any stroke within the prior 30 days
- Patients in whom transesophageal echocardiography (TEE) is contraindicated since TEE is used for both preoperative screening and guidance during implant procedure
- Patients with clinical/anatomical conditions unsuitable for a transapical surgical approach
- Patients with active infection or endocarditis (suspect endocarditis included)
- Patients which suffered an acute myocardial infarction within 30 days of the intended treatment (defined as: Q wave MI, or non-Q wave MI with elevation of CK-MB ≥ 3 times normal in the absence of pathological Q waves), if no assay for CK-MB was performed, elevation of CK level to >2 times normal without new Q waves, or elevated Troponin level is also considered a non-Q wave MI)
- Patients with a documented allergy towards contrast media, and to any compound of the investigated medical device
- Patients that have neurological disease severely affecting ambulation or day to day functioning
- Patients with senile dementia, according to the advice from a specialized neurologist
- Patients who is unwilling or deemed by the Investigator to be unwilling to comply with the requirements of the protocol, or subject with a history of non-compliance
- Clinical exclusion criteria (preoperative screening)
- Patients needing emergency or life-saving interventions
- Patients with a heavily calcified mitral annulus and/or anterior mitral leaflet
- Patients with echocardiographic evidence of intracardiac mass or thrombus
- Patients unable to understand and sign the Informed Consent Form in absence of legal representative
- Patients with a lack of capacity to consent
- Patients unable to read and write; Echographic exclusion criteria (preoperative screening)
- Patients with left ventricular apex aneurysm
- Patients with aorto-mitral angle <120°
- Patients with a systolic/diastolic mitral valve area assessed as not compatible with the sizing policy matrix defined by the Sponsor; Computerized Tomographic (CT) exclusion criteria (preoperative screening)
- Patients with ventricular morphology (position of papillary muscles, ventricular wall hypertrophy) unsuitable with the study valve design
- Patients with aorto-mitral angle <120°
- Patients with a systolic/diastolic mitral valve area assessed as not compatible with the sizing policy matrix defined by the Sponsor
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
4 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device.
A teljes eredeti leírásKevesebb
The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent.
The purpose of this trial is to assess the safety and feasibility of the Epygon™ Transcatheter mitral valve and the transapical delivery system, in adult patients with severe, symptomatic mitral regurgitation.
A vizsgálat csoportja
- Implanted patientsA vizsgált kezelés
Implantation of Epygon mitral valve prosthesis
Kezelés: Epygon™ Transcatheter Mitral Valve System
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- First-In-Human Clinical Study for Treatment of Severe Mitral Valve INsufficiency With Epygon™ TRanscatheter Mitral VAlve System (MINERVA FIH)
- A regiszteradat frissítve
- 2023. augusztus 7.